Vergleich

Reserpine

ArtNr CS-1913-100mg
Hersteller ChemScene
Menge 100mg
Kategorie
Typ Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 50-55-5
Lieferbar
CAS
50-55-5
Purity
>98%
Formula
C33H40N2O9
MWt
608.68
Solubility
DMSO : 7 mg/mL (11.50 mM; Need ultrasonic)
Clinical Information
Launched
Pathway
Membrane Transporter/Ion Channel; Autophagy
Target
Monoamine Transporter; Autophagy
Biological Activity
Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). IC50 & Target: VMAT2[1] In Vitro: Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). Reserpine displays a significant effect on the density of dopamine D1 receptors (F2, 12=8.81, p<0.01) in the rat striatum. The affinity (Kd) for the dopamine D1 and D2 receptors during withdrawal from acute and chronic administration of reserpine is not change[1]. IC50 values of 43.9 and 54.9 uM are obtained after 1 day of treatment with Reserpine in JB6 P+ and HepG2-C8 cells, respectively. Reserpine induces luciferase activity in a dose-dependent manner at concentrations ranging from 5 to 50 uM, and no significant induction is observed at concentrations lower than 5 uM. Results demonstrate that Reserpine (2.5 to 10 uM) also increases the protein expression of Nrf2, HO-1, and NQO1. Reserpine at concentrations of 2.5 to 10 uM decreases the mRNA expression of DNMT1, DNMT3a, and DNMT3b in a concentration-dependent manner in JB6 P+ cells after 7 days of treatment. Reserpine at 10 uM generates a significant difference for DNMT3a expression (p<0.05)[2]. In Vivo: Withdrawal (48 h) from chronic (14-day) but not acute Reserpine administration in a dose of 0.2 mg/kg i.p. produces a significant reduction of the immobility time (F2, 18=3.68, p<0.05), but increases the climbing time (F2, 18=4.48, p<0.02), and does not change the swimming time (F2, 18=1.78; NS) in the forced swim test (FST) in rats[1]. Reserpine at a dose of 5 mg/kg body weight produces significant increase in the urinary excretion profile of vanillylmandelic acid (VMA) compare to control animals. The amount of 5-hydroxyindoleacetic acid (5-HIAA) excreted in animals treated with Reserpine is found to be more than in the control. Dose dependent hypotension is observed with Reserpine. Reserpine at doses of 0.5, 1, 5, 10 and 15 ug/kg produce significant (p<0.01) reduction in blood pressure compare to control[3].

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen